Cancer-associated_cachexia

Combined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

BACKGROUND

Cancer cachexia is associated with rapid body wasting and cardiac dysfunction. Bisoprolol (BIS) and megestrol acetate (MA) improve selected cachexia phenotypes in the Yoshida AH-130 model, but their combined effects are not defined. We tested reduced-dose combined treatment of BIS...

🗓️ 2026-05-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCombined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

Liver-derived ceramides link metabolism to tissue wasting in cancer cachexia.

Cancer cachexia, characterized by weight loss, muscle wasting, and anorexia, complicates cancer treatment and adversely affects patient outcomes. Both tumor-derived and host inflammatory factors are implicated in aspects of cachexia. The search for circulating mediators of cancer cachexia has focused...

🗓️ 2026-05-15
📰 Publication: Journal Of Clinical Investigation
Read MoreLiver-derived ceramides link metabolism to tissue wasting in cancer cachexia.

Inhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model.

Cachexia is a metabolic wasting syndrome affecting many patients with cancer, with poor survival outcomes. Disturbed lipid metabolism is a hallmark of cachexia, and our previous work has identified increased levels of circulating ceramides, which are bioactive lipids with adverse...

🗓️ 2026-05-15
📰 Publication: Journal Of Clinical Investigation
Read MoreInhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model.

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

BACKGROUND

In a recent Phase 2 trial in patients with cancer cachexia, the anti-GDF-15 antibody ponsegromab resulted in increased body weight, appetite, muscle mass and physical activity. This study provides compelling evidence that targeting the GDF-15 pathway may offer a viable...

🗓️ 2026-05-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

MyoRep: A Novel Reporter System to Detect Early Muscle Atrophy In Vitro and In Vivo.

BACKGROUND

Muscle atrophy occurs during physiological (i.e., fasting) and pathological conditions (i.e., cancer) and anticipates death. Since not all patients will undergo muscle wasting, it would be highly useful to identify them soon to intervene early. We aim to generate a...

🗓️ 2026-05-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMyoRep: A Novel Reporter System to Detect Early Muscle Atrophy In Vitro and In Vivo.

Differential Branched-Chain Amino Acid Metabolism in Tissues of Tumor-Bearing Male Mice.

Cancer cachexia is a multifactorial syndrome characterized by involuntary loss of skeletal muscle and adipose tissue that is often resistant to nutritional support. The branched-chain amino acids (BCAA: leucine, isoleucine, and valine) stimulate protein synthesis, yet BCAA-targeted therapies have yielded...

🗓️ 2026-05-13
📰 Publication: American Journal Of Physiology-Regulatory Integrative And Comparative Physiology
Read MoreDifferential Branched-Chain Amino Acid Metabolism in Tissues of Tumor-Bearing Male Mice.

RAGE Re-Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions.

BACKGROUND

Cancer cachexia (CC) is a highly debilitating syndrome characterized by loss of body and muscle weight affecting most advanced cancer patients. The receptor for advanced glycation end-products (RAGE) is expressed by several cell types and sustains the inflammatory response in...

🗓️ 2026-05-09
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRAGE Re-Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions.

De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

Growth differentiation factor-15 (GDF15), a stress-responsive cytokine of the transforming growth factor-β superfamily, is elevated in cancer cachexia, chemotherapy-induced nausea, and hyperemesis gravidarum, making it both a biomarker and a therapeutic target. Here, we developed high-affinity GDF15 binders using an...

🗓️ 2026-05-09
📰 Publication: Experimental And Molecular Medicine
Read MoreDe novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

FcRn function alone cannot account for elevated IgG clearance in the Lewis lung carcinoma model of cancer cachexia.

PURPOSE

The neonatal Fc receptor (FcRn) protects IgG-based monoclonal antibodies (mAbs) from catabolism by direct binding within endosomes and facilitates their recycling to extracellular spaces. Elevated clearance of immune checkpoint inhibitors (ICIs) and other IgG-based mAbs is often observed in patients...

🗓️ 2026-05-09
📰 Publication: International Immunopharmacology
Read MoreFcRn function alone cannot account for elevated IgG clearance in the Lewis lung carcinoma model of cancer cachexia.

Micheliolide ameliorates colon cancer cachexia by modulating gut microbiota-immune signaling via Phocaeicola vulgatus enrichment.

BACKGROUND

Cancer cachexia profoundly impacts patient survival and quality of life. Current treatments fail to halt this trajectory, highlighting an urgent clinical need for host-directed therapies capable of uncoupling skeletal muscle wasting from tumor progression. This study investigated the therapeutic potential...

🗓️ 2026-05-06
📰 Publication: Microbiome
Read MoreMicheliolide ameliorates colon cancer cachexia by modulating gut microbiota-immune signaling via Phocaeicola vulgatus enrichment.

The Eubacterium Rectale Derived Extracellular Vesicles Alleviate Cancer Cachexia Induced Lipolysis by Inhibiting Macrophage Polarization.

Cancer cachexia (CC) is a complex pathological condition associated with cancer progression and poor prognosis, particularly in gastrointestinal cancers, and is closely linked to the gut microbiota. Lipolysis in CC may play a key role in driving cachexia progression. However,...

🗓️ 2026-05-06
📰 Publication: Journal Of Extracellular Vesicles
Read MoreThe Eubacterium Rectale Derived Extracellular Vesicles Alleviate Cancer Cachexia Induced Lipolysis by Inhibiting Macrophage Polarization.

Biosacetalin (1,1-Diethoxyethane) Prolongs Survival and Alleviates Cachexia in the NSG Mice Bearing Neuroblastoma SH-SY5Y Cells.

Neuroblastoma remains a formidable pediatric malignancy characterized by profound metabolic plasticity and limited therapeutic responsiveness in high-risk disease. Emerging evidence positions the interplay between Reactive Oxygen Species (ROS) and the metabolic sentinel AMP-activated protein kinase (AMPK) as a critical regulator...

🗓️ 2026-05-04
Read MoreBiosacetalin (1,1-Diethoxyethane) Prolongs Survival and Alleviates Cachexia in the NSG Mice Bearing Neuroblastoma SH-SY5Y Cells.

Cancer cachexia induces senescent reprogramming of brown adipose tissue and pro-cachectic S100A9 secretion by adipocytes.

Cancer-associated cachexia (CAC) is a multifactorial wasting syndrome characterized by progressive loss of fat and lean mass, systemic inflammation, and poor therapeutic responsiveness. While brown adipose tissue (BAT) is traditionally considered a protective, energy-dissipating organ, its qualitative remodeling in CAC...

🗓️ 2026-05-03
📰 Publication: Cell Death & Disease
Read MoreCancer cachexia induces senescent reprogramming of brown adipose tissue and pro-cachectic S100A9 secretion by adipocytes.

The pathology and diagnosis of cancer cachexia and a treatment insight from natural products: A review.

Cancer cachexia, which is characterized by weight loss and muscle wasting with or without fat depletion, is a complex syndrome that commonly seen in patients with advanced cancer. The underlying pathophysiological mechanisms of cancer cachexia involve in systemic inflammation, abnormal...

🗓️ 2026-04-30
📰 Publication: Biochimica Et Biophysica Acta-Reviews On Cancer
Read MoreThe pathology and diagnosis of cancer cachexia and a treatment insight from natural products: A review.

Cancer IDO1-Mediated Tryptophan-Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration.

BACKGROUND

Cancer cachexia is a debilitating syndrome characterized by severe skeletal muscle wasting, which significantly impairs patient quality of life and survival. Indoleamine 2,3-dioxygenase 1 (IDO1), a key enzyme in tryptophan (Trp) metabolism, is often upregulated in cancers, but its specific...

🗓️ 2026-04-24
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCancer IDO1-Mediated Tryptophan-Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration.

Cancer cachexia: A tumor-driven disorder of whole-body homeostasis.

Cancer cachexia is a systemic metabolic syndrome driven by tumor-induced disruption of whole-body homeostasis. Characterized by skeletal muscle atrophy and adipose tissue loss, cachexia leads to functional decline, impaired quality of life, reduced treatment tolerance, and poor survival across multiple...

🗓️ 2026-04-18
📰 Publication: Cancer Cell
Read MoreCancer cachexia: A tumor-driven disorder of whole-body homeostasis.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!